Effect of Cranberry Extract on Infections in Burn Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bacterial infections are a common complication in patients suffering from burns. These infections can cause significant morbidity and often mortality. Antimicrobial resistance coupled with the prevalence of burn-related infections warrants the identification of alternative substances in the treatment of burn-related infections. The cranberry has been examined as a potential agent in the prevention of other types of infections and it appears to have anti-adherence effects on bacteria. In addition, the cranberry has demonstrated general inhibitory effects against some types of bacteria suggesting that it may be a useful agent in the prevention of bacterial infections in burn patients. The purpose of the present study is to investigate the effect of cranberry extract on the incidence of infections in burn patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Care Study on Burn Patients

NCT01302457

Burn

WITHDRAWN

Understanding the Burn Wound Microbiome: Comparing Traditional Wound Cultures to Next Generation Sequencing Technology

NCT05275335

Microbial Colonization Burns

RECRUITING

Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks

NCT00675922

Burn

TERMINATED PHASE2/PHASE3

Microbiome Changes in Severe Burns

NCT03130868

Burns Greater Than 20% BSAB Burns

COMPLETED

Antimicrobial Resistance of Bacteria in Burn Patients

NCT00794742

Burns

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods

Design. The present study is a prospective, randomized, double-blind, placebo-controlled study of the effect of taking three times daily doses of cranberry extract in capsule form on the incidence of infection in burn patients.

Participants. Eighty patients suffering from burns and admitted to the Saint Elizabeth Regional Medical Center Burn Center, Lincoln, NE will take place in the proposed study.

Inclusion Criteria. Patients will be asked to participate in the study if the following criteria are met:

* Patients are admitted to the Saint Elizabeth Regional Medical Center Burn Unit.
* Age 19 and older.
* Patients have an expected hospital stay of 7 days or more.
* Patients are able to consume oral medication capsules.

Exclusion Criteria. Patients will not be asked to participate in the study if any of the following are present:

* Patients have a known infection.
* Patients are not able to consume oral medication capsules.
* Patients have any known allergies to cranberry or placebo components.
* Patients have known allergy to aspirin (cranberries may contain salicylic acid).
* Patients are pregnant or breast-feeding.
* Patients are taking warfarin
* Patients with known nephrolithiasis.
* Patients with renal impairment as evidenced by a creatinine clearance that is less than predicted by Cockroft-Gault formula.

A cranberry extract standardized by Ocean Spray Cranberries, Inc. will be placed into capsules in the Saint Elizabeth Regional Medical Center pharmacy. Each cranberry capsule will contain 500mg of cranberry extract. Placebo capsules will be made to look identical to cranberry capsules and will also be made at the Saint Elizabeth Regional Medical Center pharmacy. A staff pharmacist will separate the capsules into a cranberry extract group and a placebo group. A staff pharmacist will randomly assign patients to either the cranberry extract group or the placebo group. The patient, physicians, and research staff involved in data collection will be blinded to patient group assignment.

Procedure. After admission to the burn unit and after the physician has deemed that the patient is able to consume medication capsules orally, patients meeting all other selection criteria will be asked to participate in the study. Study rationale and procedures will be described to patients and informed consent will be obtained if patients indicate a willingness to participate. Basic demographic data, burn/wound related information and information pertaining to any other infections will be obtained. Participants will be randomly assigned to either the placebo or the cranberry group. Participants will be given one capsule as soon as possible after hospital admission (or as soon as they have been deemed capable of consuming medication capsules orally) and then as close as possible to 8 hours after the first dose. Patients will then be placed on an 8 hour dosing schedule (i.e., one capsule every 8 hours). Burn wounds will be examined for any clinical signs of infection as judged by attending physician on a daily basis. The determination as to whether an infection is present vs. absent will be made by a physician utilizing specific criteria. If signs of infection are present, cultures of the wound site will be taken and bacterial type will be recorded. After initial infection, wound sites will be observed to determine if infections resolve with treatment. If treatment does not seem to eradicate the infection, another bacterial culture will be taken and bacterial analysis will be performed and recorded. Data pertaining to wound infection and wound appearance will be taken on a daily basis throughout the duration of the patient's hospital stay. In addition, information pertaining to all infections present in each patient will be recorded on a daily basis throughout the patient's entire hospital stay. The determination as to whether other infections are present vs. absent will be made by a physician utilizing specific criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inert Placebo Capsule

Group Type PLACEBO_COMPARATOR

Inert Placebo Capsule

Intervention Type DRUG

Inert substance, 3 times per day in capsule form

Cranberry Extract

Group Type EXPERIMENTAL

Cranberry Extract

Intervention Type DIETARY_SUPPLEMENT

500mg TID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cranberry Extract

500mg TID

Intervention Type DIETARY_SUPPLEMENT

Inert Placebo Capsule

Inert substance, 3 times per day in capsule form

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cranberry

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients are admitted to the Saint Elizabeth Regional Medical Center Burn Unit.
* Age 19 and older.
* Patients have an expected hospital stay of 7 days or more.
* Patients are able to consume oral medication capsules.

Exclusion Criteria

* Patients have a known infection.
* Patients are not able to consume oral medication capsules.
* Patients have any known allergies to cranberry or placebo components.
* Patients have known allergy to aspirin (cranberries may contain salicylic acid).
* Patients are pregnant or breast-feeding.
* Patients are taking warfarin
* Patients with known nephrolithiasis.
* Patients with renal impairment as evidenced by a creatinine clearance that is less than predicted by Cockroft-Gault formula.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No